Research programme: small molecule therapeutics - Wellstat Therapeutics

Drug Profile

Research programme: small molecule therapeutics - Wellstat Therapeutics

Alternative Names: PN2XXX; PNXXXX; WT 2107; WT 35021; WT 35023; WT 39006; WT 621

Latest Information Update: 06 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wellstat Therapeutics Corporation
  • Class Small molecules
  • Mechanism of Action Macrophage inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gout; Inflammation; Mycoses; Solid tumours; Stomatitis
  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 06 Oct 2016 WT 2107 is still in preclinical development for Gout in USA (Wellstat Therapeutics pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gout in USA (PO)
  • 25 Nov 2015 Discontinued - Preclinical for Non-alcoholic steatohepatitis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top